{"id":"bekinda","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Headache"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Serotonin 5-HT3 receptors are found in the central nervous system and the gastrointestinal tract. Activation of these receptors can cause nausea and vomiting. By blocking these receptors, Bekinda helps to prevent nausea and vomiting associated with chemotherapy and radiation therapy.","oneSentence":"Bekinda is a delayed-release tablet formulation of ondansetron, a serotonin 5-HT3 receptor antagonist.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:22:38.619Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of nausea and vomiting associated with chemotherapy and radiation therapy"}]},"trialDetails":[{"nctId":"NCT02246439","phase":"PHASE3","title":"BEKINDA (Ondansetron 24 mg Bimodal Release Tablets) for Vomiting Due to Presumed Acute Gastroenteritis or Gastritis","status":"COMPLETED","sponsor":"RedHill Biopharma Limited","startDate":"2014-12-08","conditions":"Gastroenteritis, Gastritis","enrollment":330},{"nctId":"NCT02757105","phase":"PHASE2","title":"Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)","status":"COMPLETED","sponsor":"RedHill Biopharma Limited","startDate":"2016-05-19","conditions":"Irritable Bowel Syndrome With Diarrhea","enrollment":127}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["RHB-102 12 mg","Ondansetron Bimodal Release Tablet 12 mg"],"phase":"phase_2","status":"active","brandName":"BEKINDA","genericName":"BEKINDA","companyName":"RedHill Biopharma Limited","companyId":"redhill-biopharma-limited","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BEKINDA is a medication that has been studied for the treatment of Irritable Bowel Syndrome With Diarrhea, Gastroenteritis, and Gastritis. It is a bimodal release tablet of ondansetron, which is a serotonin 5-HT3 receptor antagonist.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}